SCYNEXIS Inc (NASDAQ:SCYX) has earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.00.
A number of brokerages have issued reports on SCYX. ValuEngine raised SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Zacks Investment Research downgraded SCYNEXIS from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Guggenheim assumed coverage on SCYNEXIS in a research report on Tuesday, October 24th. They set a “buy” rating and a $6.00 target price on the stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. National Asset Management Inc. acquired a new stake in shares of SCYNEXIS during the second quarter worth about $551,000. GSA Capital Partners LLP increased its position in shares of SCYNEXIS by 17.1% during the third quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock worth $499,000 after purchasing an additional 30,200 shares in the last quarter. Vanguard Group Inc. increased its position in shares of SCYNEXIS by 6.0% during the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after purchasing an additional 48,978 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of SCYNEXIS during the third quarter worth about $264,000. Institutional investors and hedge funds own 31.00% of the company’s stock.
Shares of SCYNEXIS (NASDAQ:SCYX) traded down $0.05 during midday trading on Friday, reaching $1.77. The company’s stock had a trading volume of 154,613 shares, compared to its average volume of 217,435. The stock has a market cap of $49.16, a P/E ratio of -2.19 and a beta of 0.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.30 and a quick ratio of 7.30. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $3.72.
SCYNEXIS (NASDAQ:SCYX) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.03. SCYNEXIS had a negative return on equity of 64.12% and a negative net margin of 8,569.46%.
COPYRIGHT VIOLATION WARNING: “SCYNEXIS Inc (SCYX) Receives Consensus Rating of “Buy” from Analysts” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/03/scynexis-inc-scyx-receives-consensus-rating-of-buy-from-analysts.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.